Celadon Pharmaceuticals - CEL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 235
  • Forecasted Upside: 294.96%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 59.50
▼ -6.5 (-9.85%)

This chart shows the closing price for CEL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Celadon Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CEL

Analyst Price Target is GBX 235
▲ +294.96% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Celadon Pharmaceuticals in the last 3 months. The average price target is GBX 235, with a high forecast of GBX 235 and a low forecast of GBX 235. The average price target represents a 294.96% upside from the last price of GBX 59.50.

This chart shows the closing price for CEL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Celadon Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/15/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/29/2023Canaccord Genuity GroupBoost TargetSpeculative BuyGBX 210 ➝ GBX 235
6/5/2023Canaccord Genuity GroupReiterated RatingSpeculative BuyGBX 210
4/20/2023Canaccord Genuity GroupReiterated RatingSpeculative BuyGBX 210
5/30/2022Canaccord Genuity GroupInitiated CoverageSpeculative BuyGBX 210
(Data available from 7/14/2019 forward)

News Sentiment Rating

-0.63 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/15/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/15/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/15/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/14/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/14/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Celadon Pharmaceuticals logo
Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: GBX 59.50
Low: 58.75
High: 65

50 Day Range

MA: GBX 85.69
Low: 61
High: 110

52 Week Range

Now: GBX 59.50
Low: 58.75
High: 165

Volume

91,586 shs

Average Volume

42,769 shs

Market Capitalization

£39.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Celadon Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Celadon Pharmaceuticals in the last twelve months: Canaccord Genuity Group Inc..
View the latest analyst ratings for CEL.

What is the current price target for Celadon Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Celadon Pharmaceuticals in the last year. Their average twelve-month price target is GBX 235, suggesting a possible upside of 295.0%. Canaccord Genuity Group Inc. has the highest price target set, predicting CEL will reach GBX 235 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of GBX 235 for Celadon Pharmaceuticals in the next year.
View the latest price targets for CEL.

What is the current consensus analyst rating for Celadon Pharmaceuticals?

Celadon Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CEL will outperform the market and that investors should add to their positions of Celadon Pharmaceuticals.
View the latest ratings for CEL.

What other companies compete with Celadon Pharmaceuticals?

How do I contact Celadon Pharmaceuticals' investor relations team?

Celadon Pharmaceuticals' physical mailing address is 32-33 Cowcross Street, London EC1M 6DF, United Kingdom. The company's listed phone number is 44 20 3150 0252. The official website for Celadon Pharmaceuticals is www.celadonpharma.co.uk. Learn More about contacing Celadon Pharmaceuticals investor relations.